Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 1;12(6):e0179064.
doi: 10.1371/journal.pone.0179064. eCollection 2017.

Genetic diversity of hepatitis C virus in Ethiopia

Affiliations

Genetic diversity of hepatitis C virus in Ethiopia

Gadissa Bedada Hundie et al. PLoS One. .

Abstract

Hepatitis C virus (HCV) is genetically highly divergent and classified in seven major genotypes and approximately hundred subtypes. These genotypes/subtypes have different geographic distribution and response to antiviral therapy. In Ethiopia, however, little is known about their molecular epidemiology and genetic diversity. The aim of this study was to investigate the distribution and genetic diversity of HCV genotypes/subtypes in Ethiopia, using 49 HCV RNA positive samples. HCV genotypes and subtypes were determined based on the sequences of the core and the nonstructural protein 5B (NS5B) genomic regions. Phylogenetic analysis revealed that the predominant was genotype 4 (77.6%) followed by 2 (12.2%), 1 (8.2%), and 5 (2.0%). Seven subtypes were identified (1b, 1c, 2c, 4d, 4l, 4r and 4v), with 4d (34.7%), 4r (34.7%) and 2c (12.2%) as the most frequent subtypes. Consistent with the presence of these subtypes was the identification of a potential recombinant virus. One strain was typed as genotype 2c in the NS5B region sequence and genotype 4d in the core region. In conclusion, genotype 4 HCV viruses, subtypes 4d and 4r, are most prevalent in Ethiopia. This genotype is considered to be difficult to treat, thus, our finding has an important impact on the development of treatment strategies and patient management in Ethiopia.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Bayesian inference phylogenetic tree of the NS5B region.
A phylogenetic tree was constructed based on the NS5B region (356 nucleotides), corresponding to nucleotide numbering of 8288–8643 in the H77 genome, using the GTR+I+G model of evolution. Numbers on branches are posterior probabilities from the Bayesian inference analysis. Reference sequences are labeled to the right of each branch in the order of subtype hyphen GenBank accession number. Ethiopian sequences are shown in color (color corresponding to their geographic origin: Red = Addis Ababa; Blue = Adama; Green = Mekelle; Pink = Gondar; Light blue = Jimma), a potential recombinant MK32ETH highlighted in yellow.
Fig 2
Fig 2. Bayesian inference phylogenetic tree of the core region.
A phylogenetic tree was constructed based on the core region (418 nucleotides), corresponding to nucleotide numbering of 300–717 in the H77 genome, using the GTR+I+G model of evolution. Numbers on branches are posterior probabilities from the Bayesian inference analysis. Reference sequences are labeled to the right of each branch in the order of subtype hyphen GenBank accession number. Ethiopian sequences are shown in color (color corresponding to their geographic origin: Red = Addis Ababa; Blue = Adama; Green = Mekelle; Pink = Gondar; Light blue = Jimma), a potential recombinant MK32ETH highlighted in yellow.

References

    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342. doi: 10.1002/hep.26141 - DOI - PubMed
    1. de Oliveria Andrade LJ, D'Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Parana R. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis. 2009;1(1):33–37. doi: 10.4103/0974-777X.52979 - DOI - PMC - PubMed
    1. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–1088. doi: 10.1016/S0140-6736(16)30579-7 - DOI - PMC - PubMed
    1. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–1396. doi: 10.1086/652283 - DOI - PMC - PubMed
    1. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14(2):107–115. doi: 10.1111/j.1365-2893.2006.00785.x - DOI - PubMed

LinkOut - more resources